Who Buys Amikacin from India — 514 Importers Behind a $21.1M Market

The 514 buyers of Amikacin from India can be categorized into several segments:

1. Distributors: Entities that purchase Amikacin in bulk to supply to various healthcare providers. For instance, KHAN SEHAT LTD in Pakistan, the top buyer with imports totaling $2.54 million, likely operates as a distributor, given the substantial volume of their purchases.

2. Hospital Groups: Large healthcare institutions procuring Amikacin directly for patient treatment. While specific hospital groups are not identified in the top buyers, it's common for such entities to engage in direct procurement to ensure a steady supply for their facilities.

3. Retail Chains: Pharmacy chains that stock Amikacin for retail sale. The data does not specify retail chains among the top buyers, but such entities typically purchase smaller quantities compared to distributors.

4. Government Procurement Agencies: Organizations like UNICEF or national health departments that procure medicines for public health programs. The data does not explicitly list such agencies among the top buyers, but they often engage in large-scale, tender-based purchasing to support healthcare initiatives.

5. Re-exporters: Companies that import Amikacin for the purpose of exporting to other markets. For example, entities in the United Arab Emirates, accounting for 6.1% of imports, may serve as re-export hubs due to the country's strategic location.

6. Contract Manufacturers: Firms that import Amikacin as an active pharmaceutical ingredient (API) for formulation into finished products. While specific contract manufacturers are not identified in the top buyers, this segment typically involves companies with manufacturing capabilities seeking to produce Amikacin-based formulations.

For the top five importing countries, the import regulations for Amikacin are as follows:

The demand for Amikacin in importing countries is driven by several factors:

1. Disease Prevalence: Amikacin is an aminoglycoside antibiotic used to treat severe bacterial infections, including multidrug-resistant tuberculosis (MDR-TB). Countries with high incidences of MDR-TB and other resistant infections exhibit increased demand for Amikacin.

2. Government Healthcare Programs: Many governments have initiated programs to combat antibiotic-resistant infections, leading to increased procurement of effective antibiotics like Amikacin. For example, national tuberculosis control programs often include Amikacin in their treatment regimens.

3. Universal Health Coverage Expansion: Efforts to expand healthcare access result in higher demand for essential medicines. As more individuals gain access to healthcare services, the need for antibiotics to treat infections rises correspondingly.

4. WHO Essential Medicines List Procurement: Amikacin is listed on the WHO Model List of Essential Medicines, guiding countries in prioritizing its procurement to meet public health needs. This inclusion underscores its importance in treating severe infections and influences national procurement strategies.

5. Tender-Based Purchasing: Many countries utilize tender systems for pharmaceutical procurement, aiming to secure quality medicines at competitive prices. The repeat buyer rate of 53.1% indicates a stable demand, likely influenced by such structured procurement processes.

In summary, the demand for Amikacin is bolstered by its critical role in treating severe and resistant infections, supported by government initiatives and international guidelines emphasizing its essential status in healthcare systems.

The 514 buyers of Amikacin from India can be categorized into several segments:

1. Distributors: Entities that purchase Amikacin in bulk to supply to various healthcare providers. For instance, KHAN SEHAT LTD in Pakistan, the top buyer with imports totaling $2.54 million, likely operates as a distributor, given the substantial volume of their purchases.

2. Hospital Groups: Large healthcare institutions procuring Amikacin directly for patient treatment. While specific hospital groups are not identified in the top buyers, it's common for such entities to engage in direct procurement to ensure a steady supply for their facilities.

3. Retail Chains: Pharmacy chains that stock Amikacin for retail sale. The data does not specify retail chains among the top buyers, but such entities typically purchase smaller quantities compared to distributors.

4. Government Procurement Agencies: Organizations like UNICEF or national health departments that procure medicines for public health programs. The data does not explicitly list such agencies among the top buyers, but they often engage in large-scale, tender-based purchasing to support healthcare initiatives.

5. Re-exporters: Companies that import Amikacin for the purpose of exporting to other markets. For example, entities in the United Arab Emirates, accounting for 6.1% of imports, may serve as re-export hubs due to the country's strategic location.

6. Contract Manufacturers: Firms that import Amikacin as an active pharmaceutical ingredient (API) for formulation into finished products. While specific contract manufacturers are not identified in the top buyers, this segment typically involves companies with manufacturing capabilities seeking to produce Amikacin-based formulations.

For the top five importing countries, the import regulations for Amikacin are as follows:

The demand for Amikacin in importing countries is driven by several factors:

1. Disease Prevalence: Amikacin is an aminoglycoside antibiotic used to treat severe bacterial infections, including multidrug-resistant tuberculosis (MDR-TB). Countries with high incidences of MDR-TB and other resistant infections exhibit increased demand for Amikacin.

2. Government Healthcare Programs: Many governments have initiated programs to combat antibiotic-resistant infections, leading to increased procurement of effective antibiotics like Amikacin. For example, national tuberculosis control programs often include Amikacin in their treatment regimens.

3. Universal Health Coverage Expansion: Efforts to expand healthcare access result in higher demand for essential medicines. As more individuals gain access to healthcare services, the need for antibiotics to treat infections rises correspondingly.

4. WHO Essential Medicines List Procurement: Amikacin is listed on the WHO Model List of Essential Medicines, guiding countries in prioritizing its procurement to meet public health needs. This inclusion underscores its importance in treating severe infections and influences national procurement strategies.

5. Tender-Based Purchasing: Many countries utilize tender systems for pharmaceutical procurement, aiming to secure quality medicines at competitive prices. The repeat buyer rate of 53.1% indicates a stable demand, likely influenced by such structured procurement processes.

In summary, the demand for Amikacin is bolstered by its critical role in treating severe and resistant infections, supported by government initiatives and international guidelines emphasizing its essential status in healthcare systems.